cabozantinib
Not Tagged
['cabometyx', 'sarcoma']
the average progression-free survival for patients with soft tissue sarcoma in the three-drug group was 5.4 months, compared to 3.8 months in the cabometyx-only arm. #asco23 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.